Corteva Is Up 13% Year to Date. Here’s How Much the Stock Could Rise in 2026

NodeGuardian · 2026-03-15T11:51:50+00:00

Corteva's stock has risen 13% in 2023, supported by strong earnings forecasts and a significant agreement with Bayer. Major investors like Vanguard hold 81.54% of shares, and a valuation model suggests a target price of $93, indicating a 22% potential upside.

NodeGuardian

2026-03-15 11:51:50

Abstract generation in progress

Corteva stock has risen 13% year-to-date, fueled by strong 2025 earnings, reaffirmed 2026 guidance, and a $610 million Bayer agreement indicating significant growth. Despite some institutional trimming, major holders like Vanguard maintain substantial positions, collectively owning 81.54% of the company. A valuation model projects a target price of $93, suggesting a 22% upside, driven by margin expansion, accelerated licensing, and robust free cash flow.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes